Glioblastoma treatment lucicebtide well tolerated in clinical trial

Glioblastoma treatment lucicebtide well tolerated in clinical trial

Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of glioma, a form of brain cancer. Trial data also indicate that the therapy is working as expected and that it may help delay cancer progression. That’s according to data that Sapience Therapeutics, the therapy’s developer, shared at the American Society of Clinical Oncology’s annual meeting, held…